|
|
| | N-(2-hydroxyethyl)-4-(6-(4-(trifluoromethoxy)phenylamino)pyrimidin-4-yl)benzamide Basic information |
| Product Name: | N-(2-hydroxyethyl)-4-(6-(4-(trifluoromethoxy)phenylamino)pyrimidin-4-yl)benzamide | | Synonyms: | N-(2-hydroxyethyl)-4-(6-(4-(trifluoromethoxy)phenylamino)pyrimidin-4-yl)benzamide;Multi-kinase inhibitor I;MDK74978(Multi-kinase inhibitor);MDK74978;MDK 74978. Multi-kinase inhibitor I;MDK74978; MDK-74978; MDK 74978. MULTI-KINASE INHIBITOR I;MDK74978;MDK-74978;Benzamide, N-(2-hydroxyethyl)-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- | | CAS: | 778274-97-8 | | MF: | C20H17F3N4O3 | | MW: | 418.37 | | EINECS: | | | Product Categories: | | | Mol File: | 778274-97-8.mol |  |
| | N-(2-hydroxyethyl)-4-(6-(4-(trifluoromethoxy)phenylamino)pyrimidin-4-yl)benzamide Chemical Properties |
| storage temp. | Store at 0-8 °C | | form | Solid | | color | Off-white to yellow |
| | N-(2-hydroxyethyl)-4-(6-(4-(trifluoromethoxy)phenylamino)pyrimidin-4-yl)benzamide Usage And Synthesis |
| Uses | Multi-kinase inhibitor 1 is a potent multi-kinase inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl[1]. | | IC 50 | PDGFR; Bcr-Abl | | References | [1] Qiang Ding, et al. Novel compounds and compositions as protein kinase inhibitors. WO2004089286A2. |
| | N-(2-hydroxyethyl)-4-(6-(4-(trifluoromethoxy)phenylamino)pyrimidin-4-yl)benzamide Preparation Products And Raw materials |
|